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Abstract
Introduction:  Laser  Vision  Correction  is  not  always  possible  for  the  treatment  of  myopia.  The
aim of  this  paper  is  to  present  results  after  MyoRing  implantation  in  myopic  eyes  who  in  their
majority were  not  eligible  for  LVC.  Safety,  effectivity  and  patient  selection  is  discussed.  The
aim of  the  treatment  was  to  be  spectacle  independent  in  everyday-life.
Materials  and  methods:  19  myopic  eyes  of  12  patients  ranging  from  −2.25  to  −16.5  dioptres
(D) in  sphere  and  from  0  to  −4  D  in  cylinder  were  analyzed.
Results:  After  treatment,  84%  of  the  eyes  reached  uncorrected  distance  visual  acuity  (UDVA)
of 0.5  or  better,  42%  reached  UDVA  of  0.8  or  better  and  16%  reached  UDVA  of  1.0  or  better.
Before treatment,  no  eye  reached  UDVA  of  0.5  or  better.  Corrected  distance  visual  acuity  (CDVA)
preoperatively  and  postoperatively  did  not  differ.  The  treatment  changed  the  average  spherical
equivalent from  −10.27  D  to  −0.93  D.  Efﬁcacy  index  was  0.76  and  safety  index  was  1.02.
Conclusion:  MyoRing  implantation  for  myopia  is  safe  and  effective  with  highly  satisﬁed  patents
in a  particular  subgroup  of  myopic  patients.  Patient  selection  is  important.
© 2016  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Resumen
Introducción:  La  corrección  de  la  visión  con  láser  (CVL)  no  es  siempre  posible  en  el  tratamiento
de la  miopía.  El  objetivo  de  este  artículo  es  presentar  los  resultados  tras  la  implantación  deLIO  fáquicas;
MyoRing;
CISIS
MyoRing en  ojos  miopes  que,  en  su  mayoría,  no  son  aptos  para  la  CVL.  Se  tratan  cuestiones  tales
como la  seguridad,  la  efectividad  y  la  selección  de  los  pacientes.  El  objetivo  del  tratamiento
fue el  de  eliminar  el  uso  de  gafas  en  la  vida  diaria.Please  cite  this  article  in  press  as:  Daxer  A.  MyoRing  treatment  of  myopia.  J  Optom.  (2016),
http://dx.doi.org/10.1016/j.optom.2016.06.003
∗ Correspondence to: GutSehen Eye Center, Stauwerkstrasse 1, 3370 Ybbs, Austria.
E-mail address: daxer@gutsehen.at
http://dx.doi.org/10.1016/j.optom.2016.06.003
1888-4296/© 2016 Spanish General Council of Optometry. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Materiales  y  Métodos:  Se  analizaron  19  ojos  miopes  de  12  pacientes,  con  un  rango  de  -2,25  a
-16,5 dioptrías  (D)  de  esfera,  y  de  0  a  -4  D  de  cilindro.
Resultados:  Tras  el  tratamiento,  el  84%  de  los  ojos  logró  una  agudeza  visual  lejana  sin  corrección
(UDVA) de  0,5  o  superior,  el  42%  logró  una  UDVA  de  0,8  o  superior,  y  el  16%  logró  una  UDVA  de
1,0 o  superior.  Con  anterioridad  al  tratamiento,  ningún  ojo  logró  una  UDVA  de  0,5  o  superior.  La
agudeza visual  lejana  corregida  (CDVA)  no  diﬁrió  con  anterioridad  y  posterioridad  a  la  operación.
El tratamiento  modiﬁcó  el  equivalente  esférico  medio  de  -10,27  D  a  -0,93  D.  El  índice  de  eﬁcacia
fue de  0,76  y  el  índice  de  seguridad  de  1,02.
Conclusión:  La  implantación  de  MyoRing  en  pacientes  miopes  es  segura  y  efectiva,  con  elevada
satisfacción  por  parte  de  un  subgrupo  especíﬁco  de  pacientes  miopes.  Es  importante  la  selección
de los  pacientes.
©  2016  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
I
L
t
p
O
a
m
i
l
i
i
g
M
s
m
a
t
M
N
g
s
w
o
D
e
t
s
e
h
A
i
h
s
p
a
p
f
(
2
T
U
t
A
R
P
(
T
o
e
r
T
f
n
A
t
w
d
b
b
8
1
t
e
t
o
s
C
0ntroduction
aser  Vision  Correction  (LVC)  offers  a  safe  and  effective
reatment  of  myopia.1 However,  a  signiﬁcant  number  of
atients  seeking  for  LVC  are  not  eligible  for  that  treatment.
ne  reason  is  the  risk  of  severe  long-term  complications  such
s  corneal  ectasia.2 Risk  factors  include  thin  cornea  and  high
yopia.3 In  high  myopia,  postoperative  ectasia  can  develop
n  up  to  2.5%  of  the  cases.4 Implantation  of  phakic  intraocu-
ar  lenses  (pIOL)  is  often  considered  as  an  alternative  option
n  many  cases  of  high  myopia.  Complications  after  pIOL
nclude  clinically  signiﬁcant  cataract  formation  in  some  7%,
laucoma  in  some  7%  and  endothelial  decompensation.5--7
Corneal  intrastromal  implantation  surgery  (CISIS)  with
yoRing  implantation  into  a  corneal  pocket  has  been  demon-
trated  to  be  able  to  treat  keratoconus8--11 and  to  correct
oderate  to  high  myopia  successfully.12 Here  I report  about
 sample  of  mild,  moderate  and  high  myopic  cases  I  have
reated  by  means  of  CISIS  with  MyoRing.
aterials and methods
ineteen  myopic  eyes  of  12  patients  without  any  topo-
raphic  sign  of  manifest  keratoconus  are  included  in  this
tudy.  This  is  a  retrospective  study  which  enrolls  patients
hom  I  treated  during  the  past  8  years  and  who  had  a  post-
perative  examination  in  my  center  between  July  1  and
ecember  31,  2015.  Informed  consent  was  obtained  from
very  patient  prior  to  surgery.
Eighteen  of  19  eyes  were  not  eligible  for  LVC  and  1  was
reated  just  because  he  wanted  neither  LVC  nor  pIOL  but  a
afe  and  reversible  treatment.  Sixteen  of  the  18  eyes  not
ligible  for  LVC  were  treated  because  of  thin  cornea  and/or
igh  myopia,  while  2  because  of  rheumatoid  arthritis  (RA).
lthough  RA  is  also  mentioned  as  a  contraindication  in  the
nstruction  for  use  (IFU)  of  MyoRing,  the  patient  insisted  in
aving  any  kind  of  surgical  correction  and  we  achieved  con-Please  cite  this  article  in  press  as:  Daxer  A.  M
http://dx.doi.org/10.1016/j.optom.2016.06.003
ent  to  perform  MyoRing  implantation  with  short  follow-up
eriods  to  be  able  to  detect  a  possible  ring  extrusion  early
nd  to  remove  the  ring  immediately  when  it  seems  to  hap-
en  in  order  to  avoid  harming  the  cornea.  The  analyzed
a
e
collow-up  period  ranged  from  2  months  to  24  months
median  6  months).  The  age  of  the  patients  ranged  from
1  to  46  years  at  the  time  of  treatment  (median  28  years).
able  1  shows  the  nomogram  used  in  the  study.
The  treatment  were  perfomed  using  the  PocketMaker
ltrakeratome  (DIOPTEX  GmbH,  Austria)  for  the  creation  of
he  corneal  pocket  followed  by  MyoRing  (DIOPTEX  GmbH,
ustria)  implantation  as  described  elsewhere.8
esults
reoperative  sphere  ranged  from  −2.25  to  −16.5  dioptres
D)  and  preoperative  cylinder  ranged  from  0  to  −4.0  D.
able  2 shows  comparison  between  preoperative  and  post-
perative  spherical  equivalent  and  the  corrective  power  for
very  MyoRing  dimension  used.  The  corrective  power  cor-
esponds  well  to  the  change  in  central  average  K  reading.
able  3  shows  sphere  and  cylinder  pre-  and  postoperatively
or  every  MyoRing  dimension  used.
Uncorrected  distance  visual  acuity  (UDVA)  improved  sig-
iﬁcantly  from  1.77  ±  0.5  to  0.23  ±  0.3  (logMAR)  in  average.
s  a  measure  of  the  effectivity  of  the  treatment,  postopera-
ive  UDVA  was  in  average  1.8  lines  below  preoperative  CDVA
hich  resulted  in  an  efﬁcacy  index  of  0.76.  Fig.  1  shows  the
istribution  of  preoperative  and  postoperative  UDVA.  While
efore  treatment  only  21%  of  the  eyes  had  UDVA  of  0.05  or
etter  and  no  eye  (0%)  had  0.5  or  better,  after  treatment
4%  of  the  eyes  had  UDVA  of  0.5  or  better  and  even  16%  had
.0  or  better.
Corrected  distance  visual  acuity  (CDVA)  remained  prac-
ically  unchanged  between  preoperative  and  postoperative
xamination  resulting  in  a  safety  index  of  1.02.  Preopera-
ively,  all  eyes  (100%)  had  CDVA  of  0.5  or  better,  80%  had  0.8
r  better  and  even  74%  had  CDVA  of  1.0  or  better.  Fig.  2
hows  the  distribution  of  preoperative  and  postoperative
DVA.  Only  one  eye  changed  from  CDVA  (decimal)  less  than
.8  to  0.8  or  better.  Table  4  shows  the  visual  acuity  beforeyoRing  treatment  of  myopia.  J  Optom.  (2016),
nd  after  treatment.
The  aim  of  the  treatment  were  not  to  guarantee
mmetropia  but  to  be  able  to  handle  daily  life,  including
ar  driving  without  wearing  spactacles  or  contact  lenses.
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Table  1  The  nomogram  shows  the  dimensions  of  the  MyoRing  used  for  a  certain  refractive  correction  and  the  number  of  eyes
treated with  each  MyoRing  dimension.
MyoRing
diameter  (mm)
MyoRing  thickness
(microns)
SE  range  (dioptres)  Number  of
treatments
5  280  −9.0  to  −13.0 14
6 280  −5.5  to  −6.5 3
7 280  −2.5  to  −3.5  2
Table  2  Preoperative  and  postoperative  spherical  equivalent  (SE)  and  corrective  power  in  dioptres  for  each  MyoRing  dimension
used in  the  study.
MyoRing  diameter  (mm)  MyoRing
thickness
(microns)
SE
preoperatively
(dioptres)
SE
postoperatively
(dioptres)
Corrected
power
(dioptres)
5  280  −11.72  ±  2.6  −0.88  ±  1.2  10.8  ±  1.4
6 280  −6.83  ±  0.8  −0.67  ±  0.8  6.17  ±  0.2
7 280  −2.81  ±  0.3  +0.5  ±  0.0  3.31  ±  0.3
The values show mean and standard deviation.
Table  3  Preoperative  and  postoperative  sphere  (sph)  and  cylinder  (cyl)  in  dioptres  for  each  MyoRing  dimension  used  in  the
study.
MyoRing  diameter  (mm)  MyoRing
thickness
(microns)
sph
preoperatively
(dioptres)
cyl
preoperatively
(dioptres)
sph
postoperatively
(dioptres)
cyl
postoperatively
(dioptres)
5  280  −11.00  ±  2.7  −1.45  ±  1.2  −0.45  ±  0.4  −0.88  ±  0.9
6 280  −7.58  ±  2.5  −1.75  ±  1.3  −1.42  ±  2  −1.33  ±  0.6
7 280  −2.5  ±  0.4  −0.63  ±  0.2  1.0  ±  0.4  −1.0  ±  0.7
The values show mean and standard deviation.
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No  relevant  complications  happened  during  or  after
surgery.  Deposits  were  seen  occasionally  at  the  implant  edgeand after  MyoRing  treatment.
The  patients  were  informed  preoperatively  that  it  may  hap-
pen  that  they  have  to  wear  spectacles  in  a  low  diopter  rangePlease  cite  this  article  in  press  as:  Daxer  A.  M
http://dx.doi.org/10.1016/j.optom.2016.06.003
for  special  occasions  such  as  night  driving.
A  total  of  20%  of  the  cases  reported  night  vision  prob-
lems  and  halos  during  an  initial  period  of  time  after  surgery
b
tigure  2  Corrected  distance  visual  acuity  (CDVA)  before  and
fter MyoRing  treatment.
ithout  spectacles  which  usually  disappeared  or  were  not
ecognized  anymore  after  3  months.yoRing  treatment  of  myopia.  J  Optom.  (2016),
ut  were  of  no  clinical  relevance.  There  was  also  no  stromal
hinning  or  dry  eye  symptoms.
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Table  4  Preoperative  and  postoperative  uncorrected
(UDVA)  and  corrected  (CDVA)  distance  visual  acuity  in
logMAR.
UDVA  (logMAR)  CDVA  (logMAR)
Preoperatively 1.77  ±  0.5 0.05  ±  0.1
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The values show mean and standard deviation.
iscussion
he  ideal  range  of  myopia  treatment  by  means  of  CISIS  with
yoRing  implantation  is  around  −10  D  sphere  with  cylinder
alues  of  less  than  −2  D.  These  patients  are  extremely  happy
hen  preoperatively  selected  in  the  right  way.  Patient  selec-
ion  is  mainly  based  upon  the  expectation  of  the  patient.  If
he  patient  is  happy  with  contact  lenses  and  it  is  important
or  him  to  have  visual  acuity  of  20/20  or  better  in  everyday
ife,  this  option  of  treatment  is  not  the  adequate.  These
atients  will  not  be  happy  at  all  and  will  ask  for  MyoRing
emoval.  Since  implantation  as  well  as  removal  of  the  MyoR-
ng  is  almost  as  simple  as  handling  a  contact  lens  without
he  need  of  a  suture,  it  might  be  not  a  big  problem  in  wrong
hosen  cases,  because  the  quick,  easy  and  painfree  way  of
yoRing  removal  (reversibility)  is  usually  one  of  the  main
riteria  of  the  patients  for  choosing  that  treatment  option.
emoving  the  MyoRing  is  just  less  than  a  one  minute  job
nd  starts  with  opening  of  the  corneal  tunnel  by  means  of  a
inskey  hook  and  reopening  the  pocket  by  means  of  a  spat-
la.  Then,  the  MyoRing  can  easily  be  extracted  by  means
f  the  Sinkey  hook.  The  corneal  tunnel  is  self  sealing  and
equires  no  suture.
The  right  patients  are  those  who  have  good  CDVA  but
ant  to  be  able  to  handle  daily  life,  including  car  driving
ithout  wearing  spectacles  or  contact  lenses  but  are  will-
ng  to  wear  spectacles  in  a  low  diopter  range  for  special
ccasions  such  as  for  instance  night  driving.  In  particular,
hose  patients  out  of  that  group  who  are  around  −10  D  (−8
o  −13  D)  of  spherical  equivalent  (SE)  are  usually  extremely
appy  and  do  not  report  relevant  side  effects  postopera-
ively.  A  second  group  of  excellent  candidates  who  almost
lways  tolerate  the  treatment  very  well  without  any  reports
f  relevant  side  effects  are  those  cases  of  moderate  and
igh  myopia  who  preoperatively  do  not  reach  CDVA  0.8  or
etter.  Most  probably,  this  is  because  these  patients  are  less
ensitive  to  additional  visual  disturbances  such  as  halos.
Regarding  the  visual  results,  it  is  important  to  note  that
fter  MyoRing  implantation,  more  than  84%  had  UDVA  of  0.5
nd  better,  42%  had  UDVA  of  0.8  or  better  and  even  16%  had
DVA  of  1.0  or  better  while  preoperatively  100%  of  the  eyes
eached  CDVA  of  0.5  or  better,  but  only  84%  reached  CDVA
f  0.8  or  better  and  only  73%  reached  CDVA  of  1.0  or  better.
hese  data  are  shown  graphically  in  Figs.  1  and  2.  It  should
e  noted  that  these  data  include  also  those  cases  where
he  correction  of  anisometropia  was  the  aim  and  not  being
lose  to  emmetropia.  Those  2  eyes  (10%)  who  did  not  reach
ntended  UDVA  of  0.5  or  better  postoperatively,  reachedPlease  cite  this  article  in  press  as:  Daxer  A.  M
http://dx.doi.org/10.1016/j.optom.2016.06.003
DVA  of  0.4.  These  eyes  had  preoperatively  −16.0  sphere
nd  −0.5  cylinder  and  −13.5  sphere  and  −3.0  cylinder.  Both
atients  were  postoperatively  happy  and  denied  removing
he  MyoRing. PRESS
A.  Daxer
Interestingly,  it  seems  that  pupil  size  does  not  play
hat  role  in  patient  selection  as  patient’s  expectations  do.
here  were  even  patients  with  relatively  large  pupils  who
olerated  the  (transparent)  MyoRing  very  well  without  com-
laining  about  halos  or  other  visual  disturbances.
A  limitation  of  that  retrospective  analysis  is  that  it  con-
iders  an  arbitrarily  selected  group  of  patients  who  visited
he  private  practice  for  postoperative  follow-up  during  a
ertain  period  of  time  (between  July  2015  and  December
015)  but  whose  treatment  have  been  completed  already
uccessfully  much  earlier.  Since  many  of  the  treated  patients
re  from  a  distant  area,  it  was  difﬁcult  to  recruit  a  large
roup  of  treated  patients  for  follow-up  after  completing
he  treatment  The  cases  presented  are  considered  a  ran-
om  sample  of  the  eyes  treated  according  to  the  reported
election  criteria.  It  does  therefore  not  include  those  cases
ho  required  removal  of  the  implant  for  not  reaching  the
isual  results  they  expected.  That  number  of  patients,  how-
ver,  can  be  kept  very  low  if  the  right  patient  selection
nd  an  appropriate  teaching  of  the  patients  as  described
bove  take  place  preoperatively.  The  presented  data  there-
ore  describe  the  visual  results  which  can  be  achieved  by
hat  method  if  the  patients  are  properly  selected  accord-
ng  to  the  criteria  described  above.  In  agreement  with  the
xperience  with  the  treatment  of  keratoconus,  no  intra-
r  postoperative  complications  have  been  observed  in  the
reatment  of  myopia.8--11
In  conclusion,  MyoRing  treatment  is  a  safe,  effective  and
ully  reversible  refractive  surgery  procedure  which  gives
xcellent  results  in  a  particular  group  of  myopic  patients
uffering  from  moderate  and  high  myopia.
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